Carmen Alonso-Cotoner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4063301/publications.pdf

Version: 2024-02-01

48 papers

2,757 citations

201385 27 h-index 243296 44 g-index

49 all docs 49 docs citations

49 times ranked

3539 citing authors

#	Article	IF	CITATIONS
1	Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut, 2007, 56, 203-209.	6.1	330
2	Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut, 2013, 62, 1160-1168.	6.1	229
3	The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations. American Journal of Gastroenterology, 2012, 107, 736-746.	0.2	169
4	A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Advances in Therapy, 2018, 35, 289-310.	1.3	152
5	The intestinal barrier function and its involvement in digestive disease. Revista Espanola De Enfermedades Digestivas, 2015, 108, 686-96.	0.1	121
6	Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis. Cells, 2019, 8, 135.	1.8	115
7	Maladaptive Intestinal Epithelial Responses to Life Stress May Predispose Healthy Women to Gut Mucosal Inflammation. Gastroenterology, 2008, 135, 163-172.e1.	0.6	112
8	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. Gut, 2017, 66, 1537.1-1538.	6.1	105
9	GEF-H1 Mediated Control of NOD1 Dependent NF-κB Activation by Shigella Effectors. PLoS Pathogens, 2008, 4, e1000228.	2.1	99
10	Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut, 2015, 64, 1379-1388.	6.1	94
11	Circulatory Antigen Processing by Mucosal Dendritic Cells Controls CD8+ T Cell Activation. Immunity, 2013, 38, 153-165.	6.6	92
12	Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. Brain, Behavior, and Immunity, 2010, 24, 1166-1175.	2.0	88
13	Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. Journal of Neurogastroenterology and Motility, 2015, 21, 033-050.	0.8	84
14	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2017, 45, 909-922.	1.9	81
15	Pathogenesis of irritable bowel syndrome: The mast cell connection. Scandinavian Journal of Gastroenterology, 2005, 40, 129-140.	0.6	74
16	Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction. Psychoneuroendocrinology, 2012, 37, 65-77.	1.3	62
17	The joint power of sex and stress to modulate brain–gut–microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. Neurogastroenterology and Motility, 2016, 28, 463-486.	1.6	62
18	Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. Psychoneuroendocrinology, 2008, 33, 1248-1256.	1.3	61

#	Article	IF	Citations
19	Toll-Like Receptor 4-Mediated Regulation of Spontaneous Helicobacter-Dependent Colitis in IL-10–Deficient Mice. Gastroenterology, 2009, 137, 1380-1390.e3.	0.6	61
20	Acute experimental stress evokes a differential genderâ€determined increase in human intestinal macromolecular permeability. Neurogastroenterology and Motility, 2012, 24, 740.	1.6	55
21	Targeting mast cells in the treatment of functional gastrointestinal disorders. Current Opinion in Pharmacology, 2006, 6, 541-546.	1.7	50
22	Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 53-63.	1.4	47
23	Intestinal Barrier Function and the Brain-Gut Axis. Advances in Experimental Medicine and Biology, 2014, 817, 73-113.	0.8	43
24	Downregulation of mucosal mast cell activation and immune response in diarrhoeaâ€irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterology Journal, 2017, 5, 887-897.	1.6	40
25	Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1. Inflammatory Bowel Diseases, 2012, 18, 603-612.	0.9	35
26	Metabotyping of Biofluids Reveals Stress-Based Differences in Gut Permeability in Healthy Individuals. Journal of Proteome Research, 2009, 8, 4799-4809.	1.8	33
27	Neuropharmacology of Stress-Induced Mucosal Inflammation: Implications for Inflammatory Bowel Disease and Irritable Bowel Syndrome. Current Molecular Medicine, 2008, 8, 258-273.	0.6	28
28	Colonic necrosis due to calcium polystyrene sulfonate (Kalimate) not suspended in sorbitol. Revista Espanola De Enfermedades Digestivas, 2013, 105, 232-234.	0.1	27
29	Cognitive and hedonic responses to meal ingestion correlate with changes in circulating metabolites. Neurogastroenterology and Motility, 2016, 28, 1806-1814.	1.6	27
30	Epidemiological and clinical profile of adult patients with Blastocystis sp. infection in Barcelona, Spain. Parasites and Vectors, 2016, 9, 548.	1.0	26
31	Anisakis Simplex-Induced Small Bowel Obstruction After Fish Ingestion: Preliminary Evidence for Response to Parenteral Corticosteroids. Clinical Gastroenterology and Hepatology, 2005, 3, 667-671.	2.4	23
32	Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome. Scientific Reports, 2020, 10, 20706.	1.6	21
33	Present and Future Therapeutic Approaches to Barrier Dysfunction. Frontiers in Nutrition, 2021, 8, 718093.	1.6	21
34	Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction. Scientific Reports, 2018, 8, 2255.	1.6	18
35	Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. American Journal of Gastroenterology, 2020, 115, 2047-2059.	0.2	16
36	Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation. Inflammatory Bowel Diseases, 2011, 17, 2416-2426.	0.9	15

#	Article	IF	CITATIONS
37	Registro informatizado de la telangiectasia hemorrágica hereditaria (Registro RiHHTa) en España: objetivos, métodos y resultados preliminares. Revista Clinica Espanola, 2018, 218, 468-476.	0.2	11
38	The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults. Advances in Therapy, 2021, 38, 2054-2076.	1.3	8
39	Editorial: A Closer Look at Mucosal Inflammation in Irritable Bowel Syndrome: Sex- and Gender-Related Disparities—Quantity, Quality, or Both?. American Journal of Gastroenterology, 2009, 104, 401-403.	0.2	5
40	Impaired intestinal molecular tightness in the mucosa of irritable bowel syndrome: what are the mediators?. Gut, 2009, 58, 161-162.	6.1	4
41	Blastocystis sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?. Biology, 2021, 10, 340.	1.3	4
42	Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations. Cells, 2022, 11, 2046.	1.8	4
43	Severity of gastrointestinal bleeding is similar between patients receiving direct oral anticoagulants or vitamin K antagonists. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	2
44	Acute Stress Impacts Clock Genes and Barrier Integrity in the Intestinal Mucosa in Health. Gastroenterology, 2017, 152, S919.	0.6	O
45	Integrated Multi-Omic Analysis Reveals Female Predominance of Deregulated Mucosal Actin Depolymerization by Decreased Tesk1-Mediated CFL1-Phosphorylation in IBS-D. Gastroenterology, 2017, 152, S721.	0.6	O
46	Stress Induces Specific Gender-Related Molecular Alterations in Barrier Regulatory Genes in the Jejunal Mucosa of Healthy. Gastroenterology, 2017, 152, S720-S721.	0.6	0
47	Anemia microcÃtica secundaria a úlcera anastomótica ileocólica. GastroenterologÃa Y HepatologÃa, 2019, 42, 111-112.	0.2	O
48	Tratamiento angiográfico percutáneo de lesión vascular colónica en paciente anticoagulada. GastroenterologÃa Y HepatologÃa, 2022, 45, 282-283.	0.2	0